In vivo monitoring of dihydroartemisininpiperaquine sensitivity in Plasmodium falciparum along the China-Myanmar border of Yunnan Province, China from 2007 to 2013

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Liu, Hui ^a   Yang, Heng Lin ^a   Tang, Lin Hua ^b   Li, Xing Liang ^a   Huang, Fang ^b   Wang, Jia Zhi ^c   Li, Chun Fu ^a   Wang, Heng Ye ^a   Nie, Ren Hua ^a   Guo, Xiang Rui ^d   Lin, Ying Xue ^d   Li, Mei ^b   Wang, Jian ^a   Xu, Jian Wei ^a  

^a Yunnan Institute of Parasitic Diseases Yunnan Provincial Centre of Malaria Research Yunnan Provincial Key Laboratory of Vector borne Diseases Control and Research   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c Tengchong County Center for Disease Control and Prevention   (China)

^d Yangjiang County Center for Disease Control and Prevention   (China)

Author keywords

China Myanmar border; Dihydroartemisinin piperaquine; In vivo test; Plasmodium falciparum; Resistance

Indexed keywords

DIHYDROARTEMISININ PLUS PIPERAQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; PIPERAQUINE; QUINOLINE DERIVATIVE;

ADOLESCENT; ADULT; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; ASEXUAL PARASITE CLEARANCE TIME; CHILD; CHINA; DISEASE CLEARANCE; FEMALE; FEVER CLEARANCE TIME; FOLLOW UP; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MYANMAR; NONHUMAN; OUTCOME ASSESSMENT; PARASITE CLEARANCE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; REINFECTION; DRUG EFFECTS; DRUG RESISTANCE; HEALTH SURVEY; KAPLAN MEIER METHOD; MALARIA, FALCIPARUM; MIDDLE AGED; PARASITEMIA; PARASITOLOGY; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; CHINA; DRUG RESISTANCE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; MYANMAR; PARASITEMIA; PLASMODIUM FALCIPARUM; PUBLIC HEALTH SURVEILLANCE; QUINOLINES; YOUNG ADULT;

EID: 84924169404     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0584-8     Document Type: Article

References (49)

1. WHO. World malaria report 2012. Geneva: World Health Organization; 2012.
2. WHO. The global plan for artemisinin resistance containment. Geneva: World Health Organization; 2011.
3. Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, et al. Novel phenotypic assays detect artemisinin-resistant Plasmodium falciparum malaria in Cambodia: In-vitro and ex-vivo drug response studies. Lancet Infect Dis. 2013; 13: 1043-9.
4. Noedl H, Se Y, Schaecher K, Smith B, Socheat D, Fukuda M. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008; 359: 2619-20.
5. Amaratunga C, Sreng S, Suon S, Phelps E, Stepniewska K, Lim P, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: A parasite clearance rate study. Lancet Infect Dis. 2012; 12: 851-8.
6. Amaratunga C, Mao S, Sreng S. Slow parasite clearance rates in response to artemether in patients with severe malaria. Lancet Infect Dis. 2013; 13: 113-4.
7. Hien TT, Thuy-Nhien NT, Phu NH. In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam. Malar J. 2012; 11: 355.
8. Phyo AP, Nkhoma S, Stepniewska K, Ashley E, Nair S, Gready R, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: A longitudinal study. Lancet. 2012; 379: 1960-6.
9. Bangchang K, Karbwang J. Emerging artemisinin resistance in the border areas of Thailand. Clin Pharmacol. 2013; 6: 307-22.
10. Kyaw MP, Nyunt MH, Chit K. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS One. 2013; 8: E57689.
11. WHO. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2006. p. 1-66.
12. MOH of People's Republic of China. From malaria control to elimination: A revised national malaria strategy 2010-2015. Beijing: Ministry of Health; 2009. p. 2-4.
13. MOH of People's Republic of China. Malaria elimination action plan 2010-2020. Beijing: Ministry of Health; 2010. p. 1-2 [in Chinese].
14. MOH of People's Republic of China. Malaria control manual. Beijing: Ministry of Health; 2007. p. 33-43 [in Chinese].
15. Martens P, Hall L. Malaria on the move: Human population movement and malaria transmission. Emerg Infect Dis. 2000; 6: 103-9.
16. Xu JW, Liu H. The challenges of malaria elimination in yunnan province, people's republic of China. Southeast Asian J Trop Med Public Health. 2012; 43: 819-24.
17. Petersen I, Eastman R, Lanzer M. Drug-resistant malaria: Molecular mechanisms and implications for public health. FEBS Lett. 2011; 585: 1551-62.
18. Bräutigam D. Local entrepreneurship in Southeast Asia and Subsaharan Africa: Networks and linkages to the global economy. Washington, DC: School of International Service, American University; 1998.
19. Cotter C, Sturrock HJW, Hsiang MS, Liu J, Phillips AA, Hwang J, et al. The changing epidemiology of malaria elimination: New strategies for new challenges. Lancet. 2013; 382: 900-11.
20. WHO. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva: World Health Organization; 2003. (WHO/RBM/HTM/2003.50) http://www.who.int/malaria/resistance.
21. WHO. Method for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009. p. 12-82.
22. Liu H, Yang HL, Xu JW, Wang JZ, Nie RH, Li CF. Artemisinin-naphthoquine combination versus chloroquine-primaquine to treat vivax malaria: An open-label randomized and non-inferiority trial in Yunnan Province, China. Malar J. 2013; 12: 409.
23. Yang HL, Yang Y, Yang PF. Monitoring Plasmodium falciparum chloroquine resistance in Yunnan Province, China, 1981-2006. Acta Trop. 2008; 108: 44-9.
24. WHO. Methods and techniques for clinical trials on antimalarial efficacy: Genotyping to identify parasite populations. Geneva: World Health Organization; 2008.
25. Nhama A, Bassat Q, Enosse S, Nhacolo A, Mutemba R, Carvalho E, et al. In vivo efficacy of artemether-lumefantrine and artesunate-Amodiaquine for the treatment of uncomplicated falciparum malaria in children: A multisite, open-label, two-cohort, clinical trial in Mozambique. Malar J. 2014; 13: 309.
26. Stepniewska K, White NJ. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar J. 2006; 5: 127.
27. Xu JW, Liao YM, Liu H, Nie RH, Havumaki J. Use of bed nets and factors that influence bed net use among Jinuo ethnic minority in Southern China. PLoS One. 2014; 9: E103780. doi: 10.1371/journal.pone.0103780.
28. Dondorp A, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009; 361: 455-67.
29. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014; 505: 50-5.
30. White NJ. Qinghaosu (artemisinin): The price of success. Science. 2008; 320: 330-4.
31. Witkowski B, Khim N, Chim P, Kim S, Ke S, Kloeug N, et al. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob Agents Chemother. 2013; 57: 914-23.
32. Mok S, Imwong M, Mackinnon MJ, Sim J, Ramadoss R, Yi P, et al. Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription. BMC Genomics. 2011; 12: 391.
33. Chotivanich K, Tripura R, Das D, Yi P, Day N, Pukrittayakamee S. Laboratory detection of artemisinin resistant Plasmodium falciparum. Antimicrob Agents Chemother. 2014; 58: 3157-61.
34. Sun XD, Zhang ZX, Liu DQ. Clinical study on the efficacy of dihyroartemisinin and piperaquine in treatment of multi-drug resistant Plasmodium falciparum [in Chinese]. Chin Trop Med. 2006; 6: 211-2.
35. Liu H, Yang HL, Zhang J, Li CF, Nie RH, Wang HY. Clinical trial on efficacy of compound dihydroartemisinin-piperaquine for treatment of uncomplicated falciparum malaria in Myanmar [in Chinese]. Chin J Parasit Parasitic Dis. 2011; 29: 296-8.
36. Huang F, Tang LH, Yang HL, Zhou SS, Sun XD, Liu H. Therapeutic efficacy of artesunate in the treatment of uncomplicated Plasmodium falciparum malaria and anti-malarial, drug-resistance marker polymorphisms in populations near the China-Myanmar border. Malar J. 2012; 11: 278.
37. Wang Z, Parker D, Meng H, Wu L, Li J, Zhao Z, et al. In vitro sensitivity of Plasmodium falciparum from China-Myanmar border area to major ACT drugs and polymorphisms in potential target genes. PLoS One. 2012; 7: E30927. doi: 10.1371/journal.pone.0030927.
38. WHO. Methods and techniques for assessing exposures to antimalarial drugs in clinical field studies. Geneva: World Health Organization; 2011.
39. WHO. Status report on artemisinin resistance. Geneva: World Health Organization; 2014.
40. Kyaw TT, Hlaing T, Thimasarn K, Mon KM, Galappaththy G, Plasai V, et al. Containing artemisinin resistance of Plasmodium falciparum in Myanmar: Achievements, challenges and the way forward. Southeast Asia J Public Health. 2014; 3: 90-4.
41. Yuan LL, Zhao H, Lanou Wu L, Li XM, Parkerd D, Xu SH, et al. Plasmodium falciparum populations from northeastern Myanmar display high levels of genetic diversity at multiple antigenic loci. Acta Trop. 2013; 125: 53-9.
42. Briena CO, Henricha P, Passia N, Fidock D. Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Curr Opin Infect Dis. 2011; 24: 570-7.
43. Krishna S, Kremsner PG. Antidogmatic approaches to artemisinin resistance: Reappraisal as treatment failure with artemisinin combination therapy. Trends Parasitol. 2013; 29: 313-7.
44. Guerin PJ, Bates SJ, Sibley CH. Global resistance surveillance: Ensuring antimalarial efficacy in the future. Curr Opin Infect Dis. 2009; 22: 593-600.
45. Song JP, Chen PQ, Xu Y. Randomized-control trial of compound dihydroartemisinin in treating uncomplicated falciparum malaria in Hainan Province of China [in Chinese]. J Guangzhou Uni of Trad Chin Med. 2004; 21: 9-12.
46. Wang SQ, Christophel EM, Lin SG. Efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Hainan [in Chinese]. Chin J Parasit Parasitic Dis. 2008; 26: 50-2.
47. Xia ZG, Yang MN, Zhou SS. Malaria situation in the People's Republic of China in 2011 [in Chinese]. Chin J Parasitol Parasit Dis. 2012; 30: 419-22.
48. Carrara VI, Lwin KM, Phyo AP, Ashley E, Wiladphaingern J, Sriprawat K, et al. Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai-Myanmar border, 1999-2011: An observational study. PLoS Med. 2013; 10: E1001398.
49. White N. Primaquine to prevent transmission of falciparum malaria. Lancet Infect Dis. 2013; 13: 175-81.